Atara Biotherapeutics, INC 8-K filings

Atara Biotherapeutics announced its third quarter 2024 financial results, highlighting progress in its pipeline and a strengthened cash position.

Atara Biotherapeutics has appointed its current Chief Financial Officer, Eric Hyllengren, to the additional role of Chief Operating Officer, effective October 14, 2024.

Atara Biotherapeutics has entered into a securities purchase agreement for a $36 million registered direct offering and appointed Gregory A. Ciongoli to its Board of Directors.

Atara Biotherapeutics announced a leadership transition, with Pascal Touchon stepping down as CEO to become Chairman, and Cokey Nguyen promoted to CEO, alongside positive clinical trial updates and financial results.

The FDA has accepted Atara Biotherapeutics' Biologics License Application for tabelecleucel (tab-cel) with a priority review, setting a target action date of January 15, 2025.

Atara Biotherapeutics has completed a 1-for-25 reverse stock split of its common stock, effective June 20, 2024.

Atara Biotherapeutics will implement a 1-for-25 reverse stock split effective June 20, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Atara Biotherapeutics held its 2024 annual meeting, where stockholders voted on several key proposals, including the election of directors, executive compensation, and a reverse stock split.

Atara Biotherapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including the planned submission of a Biologics License Application (BLA) for tab-cel in Q2 2024.

Atara Biotherapeutics announces that board member Eric Dobmeier will not seek re-election at the company's 2024 annual meeting.

Atara Biotherapeutics announced its fourth quarter and full year 2023 financial results, highlighted by progress in its allogeneic CAR T pipeline and a positive pre-BLA meeting for tab-cel, extending its cash runway into 2027.

Atara Biotherapeutics' Chief Medical Officer's employment terminated on February 2, 2024, followed by a consulting agreement effective through January 31, 2025.